FDA warns Chinese drugmaker for refusing access during inspection, Indian firm for data integrity lapses

Regulatory News

Regulatory NewsJoanne S. Eglovitch

Audit/inspectionGMPOTCPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited StatesWarning letters